<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id><journal-id journal-id-type="iso-abbrev">Rev Saude Publica</journal-id><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title>Revista de Sa&#x000fa;de P&#x000fa;blica</journal-title></journal-title-group><issn pub-type="ppub">0034-8910</issn><issn pub-type="epub">1518-8787</issn><publisher><publisher-name>Faculdade de Sa&#x000fa;de P&#x000fa;blica da Universidade de S&#x000e3;o Paulo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7243859</article-id><article-id pub-id-type="other">00603</article-id><article-id pub-id-type="doi">10.11606/s1518-8787.2020054002577</article-id><article-categories><subj-group subj-group-type="heading"><subject>Comment</subject></subj-group></article-categories><title-group><article-title>Diabetes and covid-19: more than the sum of two morbidities</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5907-5459</contrib-id><name><surname>Pititto</surname><given-names>Bianca de Almeida</given-names></name><xref ref-type="aff" rid="aff1"><sup>I</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7015-7391</contrib-id><name><surname>Ferreira</surname><given-names>Sandra Roberta G.</given-names></name><xref ref-type="aff" rid="aff2"><sup>II</sup></xref></contrib></contrib-group><aff id="aff1">
<label>I</label>
<institution content-type="orgname">Universidade Federal de S&#x000e3;o Paulo</institution>
<institution content-type="orgdiv1">Escola Paulista de Medicina</institution>
<institution content-type="orgdiv2">Departamento de Medicina Preventiva</institution>
<addr-line><named-content content-type="city">S&#x000e3;o Paulo</named-content><named-content content-type="state">SP</named-content></addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade Federal de S&#x000e3;o Paulo. Escola Paulista de Medicina. Departamento de Medicina Preventiva. S&#x000e3;o Paulo, SP, Brasil</institution>
</aff><aff id="aff2">
<label>II</label>
<institution content-type="orgname">Universidade de S&#x000e3;o Paulo</institution>
<institution content-type="orgdiv1">Faculdade de Sa&#x000fa;de P&#x000fa;blica</institution>
<addr-line><named-content content-type="city">S&#x000e3;o Paulo</named-content><named-content content-type="state">SP</named-content></addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade de S&#x000e3;o Paulo. Faculdade de Sa&#x000fa;de P&#x000fa;blica. S&#x000e3;o Paulo, SP, Brasil</institution>
</aff><author-notes><corresp id="c01"> Correspondence: Bianca de Almeida Pititto Universidade Federal de S&#x000e3;o Paulo Escola Paulista de Medicina Departamento de Medicina Preventiva Rua Botucatu, 740 04023-062 S&#x000e3;o Paulo, SP, Brasil E-mail: <email>bapititto@unifesp.br</email></corresp><fn fn-type="con"><p>Authors&#x02019; Contribution: Data collection, analysis and interpretation: BAP; study design and planning; manuscript development or review; approval of the final version; public responsibility for the content of the article: BAP, SRGF.</p></fn><fn fn-type="COI-statement"><p>Conflict of Interest: The authors declare no conflict of interest</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>5</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>54</volume><elocation-id>54</elocation-id><history><date date-type="received"><day>23</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2020</year></date></history><permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p></license></permissions><abstract><title>ABSTRACT</title><p>The coronavirus disease 2019 (covid-19) pandemic has caused a public health emergency worldwide. Risk, severity and mortality of the disease have been associated with non-communicable chronic diseases, such as diabetes mellitus. Accumulated evidence has caused great concern in countries with high prevalence of this morbidity, such as Brazil. This text shows the picture of diabetes in Brazil, followed by epidemiological data and explanatory hypothesis for the association between diabetes and covid-19. We emphasized how the burden of these two morbidities in a middle-income country has aggravated this pandemic scenario. The comprehension of this association and biological plausibility may help face this pandemic and future challenges.</p></abstract><kwd-group><kwd>Diabetes Mellitus</kwd><kwd>epidemiology</kwd><kwd>Coronavirus Infections, complications</kwd><kwd>Comorbidity</kwd><kwd>Developing Countries</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="22"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>On March 11<sup>th</sup>, 2020, the World Health Organization declared the outbreak caused by the novel coronavirus (SARS-CoV-2), the coronavirus disease 2019 (covid-19), as pandemic. The disease is responsible for more than 180 thousand deaths worldwide, with approximately 4,000 occurring in Brazil until the end of April 2020 (https://coronavirus.saude.gov.br/). Fatality rates have varied among countries depending on factors that influence both numbers of confirmed cases and registered deaths, as well as the proportion of at-risk individuals in the population (older adults, people with chronic diseases), access to health services, availability of accurate diagnostic tests and resources to deal with severe and critical cases (ICU, mechanical ventilators, trained health care professionals).</p><p>A huge number of studies has helped clarify clinical profiles of SARS-CoV-2 infection, showing consistently that the presence of chronic morbidities such as diabetes mellitus (DM) and its associated diseases (obesity, hypertension, and cardiovascular disease) represent major risk factors for the severity and prognosis of the disease, in addition to advanced age. Accumulated evidence has caused a great concern in countries with high prevalence of these morbidities such as Brazil.</p><p>This text shows the picture of diabetes in Brazil, followed by epidemiological data and explanatory hypothesis for the association between diabetes and covid-19. We also emphasize how the burden of these two morbidities in a middle-income country may aggravate this pandemic scenario.</p><sec><title>The Actual Burden of Diabetes in Brazil</title><p>Brazil is a typical example of the alarming picture of DM in emergent societies for this century, being the fourth country with the largest number of diabetic people. In 2019, it was estimated that 16.8 million individuals, aged between 20 and 79 years had DM in Brazil, with projection of 55% increase until 2045<sup><xref rid="B1" ref-type="bibr">1</xref></sup> .</p><p>In the 1980s, a multicenter prevalence study, including 21,847 Brazilians aged between 30 and 69 years submitted to oral glucose tolerance test, found that 7.6% had DM<sup><xref rid="B2" ref-type="bibr">2</xref></sup> . Most individuals had type 2 DM as occurs worldwide. We also found that almost half of individuals with DM were unaware of their condition. Even more impressive was the rate of undiagnosed DM registered in 2014 in the Estudo Longitudinal de Sa&#x000fa;de do Adulto (ELSA-Brasil&#x02014;Brazilian Longitudinal Study of Adult Health) that found the same proportion in 15,000 participants of a non-representative sample<sup><xref rid="B3" ref-type="bibr">3</xref></sup> .</p><p>A nationwide system of surveillance of risk and protective factors for chronic diseases by telephone survey (VIGITEL) in Brazil has yearly provided epidemiological data about non-communicable chronic diseases (NCCD) in individuals older than 18 years. A rate of 5.5% of self-reported DM was described in 2016 and two years later it reached 8.0%<sup><xref rid="B4" ref-type="bibr">4</xref></sup> . Since previous studies have shown that half of diabetic Brazilians were undiagnosed, those frequencies were certainly underestimated. As expected, rates vary according to age group, but also according to schooling, being 23.1% for individuals older than 65 years and 15.2% for those with less than 8 years of total schooling<sup><xref rid="B4" ref-type="bibr">4</xref></sup> .</p><p>Another aspect of DM in Brazil refers to its metabolic control. A nationwide cross-sectional study, evaluating 5,750 patients with type 2 DM attending the public health care system between 2006 and 2011<sup><xref rid="B5" ref-type="bibr">5</xref></sup> , reported a mean glycated hemoglobin (HbA1c) of 8.6% (SD 2.2). Targets (HbA1c &#x0003c;7%) recommended by scientific societies, such as the Brazilian Society of Diabetes, are achieved by a minority of patients even when a less strict target is considered. Only 48.5% of Brazilian patients sustain HbA1c &#x0003c; 8% which is poorer glycemic control than the observed in Europe and the USA. A multicenter study conducted in private health care system of Latin American countries showed that, among 878 Brazilian patients, approximately 40% had HbA1c levels higher than 7%<sup><xref rid="B6" ref-type="bibr">6</xref></sup> .</p><p>As in other countries, in Brazil, NCCD are responsible for practically two thirds of the causes of death, being 5.2% due to DM<sup><xref rid="B7" ref-type="bibr">7</xref></sup> . Furthermore, DM represents an important risk factor for cardiovascular disease (CVD), which accounts for 31.3% of deaths in Brazil<sup><xref rid="B8" ref-type="bibr">8</xref></sup> .</p><p>This scenario of high DM prevalence (mainly in older adults and low socioeconomic stratus) associated with late diagnosis and poor glycemic control has a deleterious effect on the occurrence of long-term complications of the disease &#x02013; macroangiopathy, retinopathy, nephropathy and neuropathy. Considering the covid-19 pandemic, global concerns on public health systems visibly increased, worsening the prognosis of diabetic individuals affected by the SARS-Cov-2 infection.</p></sec><sec><title>Diabetes and Covid-19: Epidemiological Evidence</title><p>Since the first reports of covid-19 in Wuhan, China, high frequencies of diabetic individuals among hospitalized patients and those with fatal outcome have shown the importance of DM as a risk factor. Currently, type 2 DM is followed by other risky conditions such as advanced age, obesity, hypertension and CVD.</p><p>A Chinese study of 1,099 individuals with covid-19 showed that among 173 with severe disease 23.7% had hypertension, 16.2% DM, 5.8% coronary heart disease, and 2.3% cerebrovascular disease<sup><xref rid="B9" ref-type="bibr">9</xref></sup> . Another study with 140 patients admitted to the hospital reported similar rates, 30% of hypertension and 12% of DM<sup><xref rid="B10" ref-type="bibr">10</xref></sup> .</p><p>The most robust one conducted in China assessed a total of 44,672 cases of covid-19<sup><xref rid="B11" ref-type="bibr">11</xref></sup> . The fatality rate was 2.3%, which differs according to age and severity of manifestations. Death occurred in 14.8% of patients older than 80 years (208 out of 1,408), 8.0% between 70 and 79 years (312 out of 3,918) and in 49.0% of severe cases (1,023 of 2,087). Among those who died and had chronic diseases, 10.5% had CVD, 7.3% DM, 6.3% chronic respiratory disease, 6.0% hypertension, and 5.6% cancer. An analysis of 52 critical ill patients reinforced the role of age, male sex (67%) and previous chronic disease (40%) as risk factors<sup><xref rid="B12" ref-type="bibr">12</xref></sup> . Authors reported that non-survivors at 28 days (n = 32) neither presented difference in relation to the time from the onset of symptomatology, type of symptoms nor radiological changes until hospitalization. Non-survivors and survivors differed by age (64.6 versus 51.9 years, respectively) and proportion of concomitant chronic diseases (53% versus 20%).</p><p>Factors associated with mortality were also analyzed in 191 severe cases in China; 54 died and 137 discharged<sup><xref rid="B13" ref-type="bibr">13</xref></sup> . The strongest association was found with coronary heart disease (OR 21.4, 95%CI 4.6-98.8), but also hypertension (OR 3.0, 95%CI 1.6-5.9), DM (OR 2.9, 95%CI % 1.3-6.1), COPD (OR 5.4, 95%CI 1.0-30.4), and multiple organ failure (OR 6.1, 95%CI 3.5-10.8) which increase the risk of death. Altered circulating biomarkers (ferritin, interleukin 6, D-dimer, troponin) were associated with fatal outcome. Considering the total of risk markers, independent predictors of mortality were older age, CVD, multiple organ failure and D-dimer concentration &#x0003e;1 mcg/mL<sup><xref rid="B13" ref-type="bibr">13</xref></sup> . Notably, DM and hypertension could have not appeared as independent predictors considering that they are mediators of cardiovascular events and mortality, which should imply underestimation of the effect of these diseases for the fatal outcomes<sup><xref rid="B13" ref-type="bibr">13</xref></sup> .</p><p>As the pandemic advanced to other continents, data from Europe and Americas have confirmed this worrying relationship between DM and covid-19 prognosis. In the Lombardy region of Italy, among 1,591 ICU patients affected between February and March 2020, 68% had at least one comorbidity, 49% systemic hypertension, 21% CVD, 17% type 2 DM, 8% cancer, and 4% COPD<sup><xref rid="B14" ref-type="bibr">14</xref></sup> .</p><p>In the USA, the Coronavirus Disease 2019&#x02013;Associated Hospitalization Surveillance Network (COVID-NET) showed that 89.3% of 178 adults had one or more underlying morbidities; the most common was hypertension (49.7%), followed by obesity (48.3%), chronic lung disease (34.6%), DM (28.3%) and CVD (27.8%). In individuals aged between 18 and 49 years, obesity was the most frequent condition, followed by chronic lung disease (primarily asthma) and DM while in those aged between 50 and 64 years the most frequent diseases were hypertension and DM<sup><xref rid="B15" ref-type="bibr">15</xref></sup> . Further report confirmed that age &#x0003e; 60 years with a BMI 30-34 kg/m<sup>2</sup> doubled the chance of being admitted to hospital (HR 2.0, p &#x0003c; 0.0001) and critical care (HR 1.8; p = 0.006) compared to age &#x0003c; 60 years with a BMI &#x0003c; 30 kg/m<sup>216</sup>.</p><p>In Brazil, data from the Ministry of Health also identify DM and previous CVD as the comorbidities mostly associated with death in individuals affected by the SARS-Cov-2. DM and CVD can be seen as the same disease since atherosclerosis is present in the natural history of long-term DM. Also, hyperglycemia can firstly manifest during an acute cardiovascular event.</p><p>The concern about the relationship between cardiometabolic diseases and covid-19 is not unprecedented. Previous studies have improved knowledge on the associations of DM and CVD with influenza epidemics, H1N1 or MERS<sup><xref rid="B17" ref-type="bibr">17</xref></sup> and this knowledge supports researchers to provide clues to manage the current pandemic.</p><p>The understanding of the biological plausibility for the association of DM and covid-19 might clarify underlying mechanisms, reinforcing possible causal relationships, thus enabling more effective prevention strategies to face viral epidemics.</p></sec><sec><title>Advances in Plausibility of the Association between DM and Covid-19 Severity</title><p>Investigations on the biological plausibility of the association between DM and the severity of covid-19 are ongoing but it remains unclear.</p><p>Adequate glycemic control reduces predisposition and improves prognosis against infections in people with DM. A recent study, including individuals without DM, showed that high levels of fasting plasma glucose were a predictor of poor outcomes and death in covid-19 patients<sup><xref rid="B18" ref-type="bibr">18</xref></sup> . Direct role of the disturbance of glucose metabolism and its contribution to the covid-19 severity has to be shown.</p><p>DM is a low-grade inflammation state, and a high-grade of systemic inflammation occurs in covid-19, reflected by elevations in inflammatory markers such as C-reactive protein, dimer-D and ferritin<sup><xref rid="B13" ref-type="bibr">13</xref></sup> . Therefore, DM and its associated diseases could provide a background to exacerbate inflammatory process contributing to the progression of covid-19 in diabetic individuals.</p><p>In the same context, the association of obesity with covid-19 could corroborate this hypothesis considering that the former is also a pro-inflammatory state and a risk factor for type 2 DM. Excessive adiposity produce cytokines and generates insulin resistance and endothelial dysfunction, an early event in atherogenesis. Reasons why obesity has been associated with covid-19 hospitalization and severity<sup><xref rid="B15" ref-type="bibr">15</xref></sup> , especially in people under 60 years of age<sup><xref rid="B16" ref-type="bibr">16</xref></sup> are under discussion. As previously mentioned, atherosclerosis is the macrovascular complication of DM and its presence could contribute to understanding the increased covid-19 severity and mortality. In some studies, and also in Brazil (unpublished data), CVD has been considered the strongest predictor of severity and mortality due to SARS-Cov-2 infection. The effect of cardiovascular causes of death on hospitalized patients, including myocarditis, arrhythmias, myocardial infarction and systemic thrombosis is highlighted in recent review<sup><xref rid="B17" ref-type="bibr">17</xref></sup> .</p><p>A possible deleterious role of medications to treat these morbidities was raised. Pathophysiological pathways of DM and hypertension were demonstrated to worsen SARS-Cov-2 infection<sup><xref rid="B19" ref-type="bibr">19</xref></sup> and some medications mechanism of action were based on these pathways. Coronaviruses were able to bind to target cells through angiotensin-converting enzyme 2 (ACE2) receptor which is expressed in several tissues. Researchers documented that ECA2 is increased in individuals with type 1 and type 2 DM and that some medications can increase ACE2 expression, such as ACE inhibitors, angiotensin 2 receptor blockers (ARB), thiazolidinediones and ibuprofen. However, no evidence indicates potential adverse effects of these agents on the prognosis of diabetic and hypertensive individuals with covid-19. Therefore, scientific societies such as the Brazilian Diabetes Society<sup><xref rid="B20" ref-type="bibr">20</xref></sup> have not recommended the withdrawal of these drugs due to SARS-Cov-2 infection<sup><xref rid="B21" ref-type="bibr">21</xref> , <xref rid="B22" ref-type="bibr">22</xref></sup> .</p></sec></sec><sec sec-type="conclusions"><title>FINAL CONSIDERATIONS</title><p>While advances in the knowledge of the relationship between DM and covid-19 occur, health professionals have experienced difficulties in clinical management and public health systems in the support of the heavy burden of these two morbidities in populations. Pathophysiological relationship must be well understood to plan preventive measures and/or to propose more effective therapeutic strategies. In this context, we could indicate some gaps regarding the severity of DM and SARS-Cov-2 infection that should be focused in future studies. It is possible that susceptibility and prognosis vary according to the type of DM, age, duration of illness, degree of glycemic control, presence of complications and medications in use.</p><p>In summary, DM in individuals with covid-19 is more than the simple sum of two morbidities in prognostic terms. Understanding underlying mechanisms of this association are urgently necessary to face the current SARS-Cov-2, to propose in effective prevention through vaccination and pharmacological agents as well as to prepare the health care systems for future challenges.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="other" id="B1-gen-2">1. International Diabetes Federation. IDF Diabetes Atlas. 9. ed. Brussels (BEL); IDF; 2019.</mixed-citation><element-citation publication-type="book" id="B1-gen-3"><person-group person-group-type="author"><collab>International Diabetes Federation</collab></person-group><source>IDF Diabetes Atlas</source><edition>9</edition><publisher-loc>Brussels (BEL)</publisher-loc><publisher-name>IDF</publisher-name><year>2019</year></element-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="other" id="B2-gen-2">2. Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Diabetes Care. 1992;15(11):1509-16. <pub-id pub-id-type="doi">10.2337/diacare.15.11.1509</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B2-gen-3"><person-group person-group-type="author"><name><surname>Malerbi</surname><given-names>DA</given-names></name><name><surname>Franco</surname><given-names>LJ</given-names></name></person-group><article-title>Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. The Brazilian Cooperative Group on the Study of Diabetes Prevalence</article-title><source>Diabetes Care</source><year>1992</year><volume>15</volume><issue>11</issue><fpage>1509</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.2337/diacare.15.11.1509</pub-id><pub-id pub-id-type="pmid">1468278</pub-id></element-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="other" id="B3-gen-2">3. Schmidt MI, Hoffmann JH, Diniz MFS, Lotufo PA, Griep RH, Bensenor IM, et al. High prevalence of diabetes and intermediate hyperglycemia &#x02013; The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetol Metab Syndr. 2014;6:123. <pub-id pub-id-type="doi">10.1186/1758-5996-6-123</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B3-gen-3"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>Hoffmann</surname><given-names>JH</given-names></name><name><surname>Diniz</surname><given-names>MFS</given-names></name><name><surname>Lotufo</surname><given-names>PA</given-names></name><name><surname>Griep</surname><given-names>RH</given-names></name><name><surname>Bensenor</surname><given-names>IM</given-names></name><etal>et al</etal></person-group><article-title>High prevalence of diabetes and intermediate hyperglycemia &#x02013; The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)</article-title><source>Diabetol Metab Syndr</source><year>2014</year><volume>6</volume><size units="pages">123</size><pub-id pub-id-type="doi">10.1186/1758-5996-6-123</pub-id></element-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="other" id="B4-gen-2">4. Minist&#x000e9;rio da Sa&#x000fa;de (BR), Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de, Departamento de An&#x000e1;lise em Sa&#x000fa;de e Vigil&#x000e2;ncia de Doen&#x000e7;as N&#x000e3;o Transmiss&#x000ed;veis. VIGITEL Brasil 2018: Vigil&#x000e2;ncia de fatores de risco e prote&#x000e7;&#x000e3;o para doen&#x000e7;as cr&#x000f4;nicas por inqu&#x000e9;rito telef&#x000f4;nico: estimativas sobre frequ&#x000ea;ncia e distribui&#x000e7;&#x000e3;o sociodemogr&#x000e1;fica de fatores de risco e prote&#x000e7;&#x000e3;o para doen&#x000e7;as cr&#x000f4;nicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2018. Bras&#x000ed;lia, DF; 2019 [cited 2020 Apr 23]. Available from: <ext-link ext-link-type="uri" xlink:href="https://portalarquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf">https://portalarquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf</ext-link>
</mixed-citation><element-citation publication-type="book" id="B4-gen-3"><person-group person-group-type="author"><collab>Minist&#x000e9;rio da Sa&#x000fa;de (BR)</collab><collab>Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de</collab><collab>Departamento de An&#x000e1;lise em Sa&#x000fa;de e Vigil&#x000e2;ncia de Doen&#x000e7;as N&#x000e3;o Transmiss&#x000ed;veis</collab></person-group><source>VIGITEL Brasil 2018: Vigil&#x000e2;ncia de fatores de risco e prote&#x000e7;&#x000e3;o para doen&#x000e7;as cr&#x000f4;nicas por inqu&#x000e9;rito telef&#x000f4;nico: estimativas sobre frequ&#x000ea;ncia e distribui&#x000e7;&#x000e3;o sociodemogr&#x000e1;fica de fatores de risco e prote&#x000e7;&#x000e3;o para doen&#x000e7;as cr&#x000f4;nicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2018</source><publisher-loc>Bras&#x000ed;lia, DF</publisher-loc><year>2019</year><date-in-citation content-type="cited-date">cited 2020 Apr 23</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://portalarquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf">https://portalarquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf</ext-link></comment></element-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="other" id="B5-gen-2">5. Viana LV, Leit&#x000e3;o CB, Kramer CK, Zucatti ATN, Jezini DL, Felicio J, et al. Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study. BMJ Open. 2013;3(9):e003336. <pub-id pub-id-type="doi">10.1136/bmjopen-2013-003336</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B5-gen-3"><person-group person-group-type="author"><name><surname>Viana</surname><given-names>LV</given-names></name><name><surname>Leit&#x000e3;o</surname><given-names>CB</given-names></name><name><surname>Kramer</surname><given-names>CK</given-names></name><name><surname>Zucatti</surname><given-names>ATN</given-names></name><name><surname>Jezini</surname><given-names>DL</given-names></name><name><surname>Felicio</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><issue>9</issue><elocation-id>e003336</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2013-003336</pub-id></element-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="other" id="B6-gen-2">6. Stewart GL, Tambascia M, Rosas Guzman J, Etchegoyen F, Ortega Carri&#x000f3;n J, Artemenko S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica. 2007;22(1):12-20. <pub-id pub-id-type="doi">10.1590/s1020-49892007000600002</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B6-gen-3"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>GL</given-names></name><name><surname>Tambascia</surname><given-names>M</given-names></name><name><surname>Rosas Guzman</surname><given-names>J</given-names></name><name><surname>Etchegoyen</surname><given-names>F</given-names></name><name><surname>Ortega Carri&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Artemenko</surname><given-names>S</given-names></name></person-group><article-title>Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America</article-title><source>Rev Panam Salud Publica</source><year>2007</year><volume>22</volume><issue>1</issue><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1590/s1020-49892007000600002</pub-id><pub-id pub-id-type="pmid">17931483</pub-id></element-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="other" id="B7-gen-2">7. Minist&#x000e9;rio da Sa&#x000fa;de (BR), DATASUS. Informa&#x000e7;&#x000f5;es de sa&#x000fa;de &#x02013; TABNET. Bras&#x000ed;lia, DF; s,d. [cited 2020 Apr 23]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www2.datasus.gov.br/DATASUS/index.php">http://www2.datasus.gov.br/DATASUS/index.php</ext-link>
</mixed-citation><element-citation publication-type="book" id="B7-gen-3"><person-group person-group-type="author"><collab>Minist&#x000e9;rio da Sa&#x000fa;de (BR)</collab><collab>DATASUS</collab></person-group><source>Informa&#x000e7;&#x000f5;es de sa&#x000fa;de &#x02013; TABNET</source><publisher-loc>Bras&#x000ed;lia, DF</publisher-loc><comment>s,d</comment><date-in-citation content-type="cited-date">cited 2020 Apr 23</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www2.datasus.gov.br/DATASUS/index.php">http://www2.datasus.gov.br/DATASUS/index.php</ext-link></comment></element-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="other" id="B8-gen-2">8. Schmidt MI, Duncan BB, Azevedo e Silva G, Menezes AM, Monteiro CA, Barreto, et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet. 2011;377(9781):1949-61. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60135-9</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B8-gen-3"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Azevedo e Silva</surname><given-names>G</given-names></name><name><surname>Menezes</surname><given-names>AM</given-names></name><name><surname>Monteiro</surname><given-names>CA</given-names></name><name><surname>Barreto</surname></name><etal>et al</etal></person-group><article-title>Chronic non-communicable diseases in Brazil: burden and current challenges</article-title><source>Lancet</source><year>2011</year><volume>377</volume><issue>9781</issue><fpage>1949</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60135-9</pub-id><pub-id pub-id-type="pmid">21561658</pub-id></element-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="other" id="B9-gen-2">9. Guan W, Ni Z, Hu Y, Liang, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020;382:1708-20. Chinese translation. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B9-gen-3"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname></name><name><surname>Ou</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Eng J Med</source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id></element-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="other" id="B10-gen-2">10. Zhang JJ, Dong X, Cao YY, Yuan YB, Yan YQ, Akdis CA, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China [published online ahead of print 2020 Feb 19]. Allergy. 2020. <pub-id pub-id-type="doi">10.1111/all.14238</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B10-gen-3"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>YY</given-names></name><name><surname>Yuan</surname><given-names>YB</given-names></name><name><surname>Yan</surname><given-names>YQ</given-names></name><name><surname>Akdis</surname><given-names>CA</given-names></name><etal>et al</etal></person-group><article-title>Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China</article-title><comment>published online ahead of print 2020 Feb 19</comment><source>Allergy</source><year>2020</year><pub-id pub-id-type="doi">10.1111/all.14238</pub-id></element-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="other" id="B11-gen-2">11. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020. <pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B11-gen-3"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention</article-title><comment>published online ahead of print, 2020 Feb 24</comment><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id></element-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="other" id="B12-gen-2">12. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published online ahead of print, 2020 Feb 24]. Lancet Respir Med. 2020. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B12-gen-3"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title><comment>published online ahead of print, 2020 Feb 24</comment><source>Lancet Respir Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id></element-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="other" id="B13-gen-2">13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B13-gen-3"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="other" id="B14-gen-2">14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-81. <pub-id pub-id-type="doi">10.1001/jama.2020.5394</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B14-gen-3"><person-group person-group-type="author"><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name><name><surname>Zanella</surname><given-names>A</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Cabrini</surname><given-names>L</given-names></name><name><surname>Castelli</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>16</issue><fpage>1574</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.5394</pub-id></element-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="other" id="B15-gen-2">15. Garg S, Kim L, Whitaker M, O&#x02019;Halloran A, Cummings C, Holstein R, et al. Hospitalized rates and characteristics of patients with laboratory-confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15);458-64. <pub-id pub-id-type="doi">10.15585/mmwr.mm6915e3</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B15-gen-3"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Whitaker</surname><given-names>M</given-names></name><name><surname>O&#x02019;Halloran</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>C</given-names></name><name><surname>Holstein</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Hospitalized rates and characteristics of patients with laboratory-confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2020</year><volume>69</volume><issue>15</issue><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6915e3</pub-id><pub-id pub-id-type="pmid">32298251</pub-id></element-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="other" id="B16-gen-2">16. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020. <pub-id pub-id-type="doi">10.1093/cid/ciaa415</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B16-gen-3"><person-group person-group-type="author"><name><surname>Lighter</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>M</given-names></name><name><surname>Hochman</surname><given-names>S</given-names></name><name><surname>Sterling</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Francois</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission</article-title><source>Clin Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa415</pub-id></element-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="other" id="B17-gen-2">17. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of Coronaviruses on the cardiovascular system: a review [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020. <pub-id pub-id-type="doi">10.1001/jamacardio.2020.1286</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B17-gen-3"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M</given-names></name><name><surname>Safavi-Naeini</surname><given-names>P</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Vardeny</surname><given-names>O</given-names></name></person-group><article-title>Potential effects of Coronaviruses on the cardiovascular system: a review</article-title><comment>published online ahead of print, 2020 Mar 27</comment><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1286</pub-id></element-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="other" id="B18-gen-2">18. Yang JK, Jin JM, Liu S, Bai P, He W, Wu F, et al. Blood glucose is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19 in Wuhan, China [preprint]. medRxiv. 2020. <pub-id pub-id-type="doi">10.1101/2020.04.08.20058040</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B18-gen-3"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JK</given-names></name><name><surname>Jin</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Blood glucose is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19 in Wuhan, China</article-title><comment>preprint</comment><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.08.20058040</pub-id></element-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="other" id="B19-gen-2">19. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id>
</mixed-citation><element-citation publication-type="journal" id="B19-gen-3"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Karakiulakis</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><issue>4</issue><size units="pages">e21</size><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id></element-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="other" id="B20-gen-2">20. Sociedade Brasileira de Diabetes. Notas de esclarecimentos da Sociedade Brasileira de Diabetes sobre o coronav&#x000ed;rus (COVID-190). S&#x000e3;o Paulo: SBD; 2020 [cited 2020 Apr 23]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.diabetes.org.br/publico/notas-de-esclarecimentos-da-sociedade-brasileira-de-diabetes-sobre-o-coronavirus-covid-19">https://www.diabetes.org.br/publico/notas-de-esclarecimentos-da-sociedade-brasileira-de-diabetes-sobre-o-coronavirus-covid-19</ext-link>
</mixed-citation><element-citation publication-type="book" id="B20-gen-3"><person-group person-group-type="author"><collab>Sociedade Brasileira de Diabetes</collab></person-group><source>Notas de esclarecimentos da Sociedade Brasileira de Diabetes sobre o coronav&#x000ed;rus (COVID-190)</source><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>SBD</publisher-name><year>2020</year><date-in-citation content-type="cited-date">cited 2020 Apr 23</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.diabetes.org.br/publico/notas-de-esclarecimentos-da-sociedade-brasileira-de-diabetes-sobre-o-coronavirus-covid-19">https://www.diabetes.org.br/publico/notas-de-esclarecimentos-da-sociedade-brasileira-de-diabetes-sobre-o-coronavirus-covid-19</ext-link></comment></element-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="other" id="B21-gen-2">21. European Society of Cardiology. Position statement of the ESC Council in ACE-Inhibitors and Angiotensin Receptor Blockers. Biot (FRA): ESC; 2020 [cited 2020 Apr 23]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang">https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</ext-link>
</mixed-citation><element-citation publication-type="book" id="B21-gen-3"><person-group person-group-type="author"><collab>European Society of Cardiology</collab></person-group><source>Position statement of the ESC Council in ACE-Inhibitors and Angiotensin Receptor Blockers</source><publisher-loc>Biot (FRA)</publisher-loc><publisher-name>ESC</publisher-name><year>2020</year><date-in-citation content-type="cited-date">cited 2020 Apr 23</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang">https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</ext-link></comment></element-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="other" id="B22-gen-2">22. Sociedade Brasileira de Cardiologia. Infec&#x000e7;&#x000e3;o pelo Coronav&#x000ed;rus 2019: (COVID-19): nota de esclarecimento. SBC Informa (Rio de Janeiro). 13 Mar 2020 [cited 2020 Apr 23]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cardiol.br/sbcinforma/2020/20200313-comunicado-coronavirus.html">http://www.cardiol.br/sbcinforma/2020/20200313-comunicado-coronavirus.html</ext-link>
</mixed-citation><element-citation publication-type="book" id="B22-gen-3"><person-group person-group-type="author"><collab>Sociedade Brasileira de Cardiologia</collab></person-group><article-title>Infec&#x000e7;&#x000e3;o pelo Coronav&#x000ed;rus 2019: (COVID-19): nota de esclarecimento</article-title><source>SBC Informa</source><publisher-loc>Rio de Janeiro</publisher-loc><day>13</day><month>3</month><year>2020</year><date-in-citation content-type="cited-date">cited 2020 Apr 23</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://www.cardiol.br/sbcinforma/2020/20200313-comunicado-coronavirus.html">http://www.cardiol.br/sbcinforma/2020/20200313-comunicado-coronavirus.html</ext-link></comment></element-citation></ref></ref-list></back></article>